Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK-FMT for Severe Acute Intestinal GVHD
NCT04269850Phase 2Terminated
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Sep 2019
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, Fecal Microbiota Transplantation Capsule in Acute Graft-Versus-Host Disease (aGvHD), sponsored by First Saint Petersburg State Medical University. Started Sep 2019; status: terminated.
02
Drugs
ruxolitinibFecal Microbiota Transplantation Capsule
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04269850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269850.